PT  - JOURNAL ARTICLE
AU  - Fendler, Wolfgang P.
AU  - Lehmann, Mona
AU  - Todica, Andrei
AU  - Herrmann, Ken
AU  - Knösel, Thomas
AU  - Angele, Martin K.
AU  - Dürr, Hans Roland
AU  - Rauch, Josefine
AU  - Bartenstein, Peter
AU  - Cyran, Clemens C.
AU  - Hacker, Marcus
AU  - Lindner, Lars H.
TI  - PET Response Criteria in Solid Tumors Predicts Progression-Free Survival and Time to Local or Distant Progression After Chemotherapy with Regional Hyperthermia for Soft-Tissue Sarcoma
AID  - 10.2967/jnumed.114.152462
DP  - 2015 Apr 01
TA  - Journal of Nuclear Medicine
PG  - 530--537
VI  - 56
IP  - 4
4099  - http://jnm.snmjournals.org/content/56/4/530.short
4100  - http://jnm.snmjournals.org/content/56/4/530.full
SO  - J Nucl Med2015 Apr 01; 56
AB  - We evaluated the prognostic accuracy of established PET and CT response criteria in patients with soft-tissue sarcoma (STS) after combined chemotherapy plus regional hyperthermia (RHT). Methods: Seventy-three patients underwent 18F-FDG PET/CT before and after 2–4 cycles of neoadjuvant chemotherapy with RHT for STS. Progression-free survival (PFS) and time to local and distant progression were among other factors correlated with response according to PET Response Criteria in Solid Tumors (PERCIST 1.0) and Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Results: Metabolic response by PERCIST (n = 44/73) was an independent predictor for PFS (P = 0.002; hazard ratio [HR], 0.35; 95% confidence interval [CI], 0.18–0.68) and time to local or distant progression. Other independent predictors for PFS by multivariate analysis were adjuvant radiotherapy (P = 0.010; HR, 0.39; 95% CI, 0.20–0.80) and a baseline tumor size less than 5.7 cm (P = 0.012; HR, 0.43; 95% CI, 0.22–0.83). Response by RECIST 1.1 was seen in a small group of patients (n = 22/73) and allowed prediction of PFS for patients with sarcoma outside the abdomen (P = 0.048; HR, 0.13; 95% CI, 0.02–0.98). Conclusion: Metabolic response by 18F-FDG PET predicts PFS and time to local and distant progression after 2–4 cycles of neoadjuvant chemotherapy plus RHT for STS.